J&J's (JNJ) Cordis Receives FDA Approval for Exoseal(TM) Vascular Closure Device
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Join SI Premium – FREE
Johnson & Johnson's (NYSE: JNJ) Cordis receives FDA approval for Exoseal(TM) vascular closure device.
Cordis says the device will be in commercial operations within the US in June.
Cordis says the device will be in commercial operations within the US in June.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- Trans Canada Gold completes phase 1 drilling at Harrison Lake project
- Hyperfine wins FDA clearance for updated portable MRI software
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
